Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 mill...

Full description

Saved in:
Bibliographic Details
Published in:Infectious diseases and therapy 2015-06, Vol.4 (2), p.145-157
Main Authors: Ustianowski, Andrew, Arends, Joop E.
Format: Article
Language:English
Subjects:
Antiretroviral drugs
HIV
Human immunodeficiency virus
Infectious Diseases
Internal Medicine
Medicine
Medicine & Public Health
Pharmacology
Review
Side effects
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c470t-14b9faed91895579c28f963789f622140249f08fecc54d8816bc244c6d9e00e03
cites cdi_FETCH-LOGICAL-c470t-14b9faed91895579c28f963789f622140249f08fecc54d8816bc244c6d9e00e03
container_end_page 157
container_issue 2
container_start_page 145
container_title Infectious diseases and therapy
container_volume 4
creator Ustianowski, Andrew
Arends, Joop E.
description Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.
doi_str_mv 10.1007/s40121-015-0070-1
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4471058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1690208645</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-14b9faed91895579c28f963789f622140249f08fecc54d8816bc244c6d9e00e03</originalsourceid><addsrcrecordid>eNp1kdFqVDEQhoNYbKl9AG8k4I03p87k5OQkXgiltFZY0YuW4lXIZiftKWeTmpxd8G18lj6ZWXYtVejVZJhv_vzDz9gbhGME6D8UCSiwAeya2kKDL9iBQNM2qtXi5e6thTD77KiUO4CKa4mmf8X2hYJWKGkO2NklxRTSesgf-fWtm_g18Qu3Jj4jl-PET8JEmffH3cPvr8M4Diny75RLis2PChSeAr8q9JrtBTcWOtrVQ3Z1fnZ5etHMvn3-cnoya7zsYWpQzk1wtDCoTdf1xgsdjGp7bYISAiUIaQLoQN53cqE1qrkXUnq1MARA0B6yT1vd-9V8SQtPccputPd5WLr8yyY32H8ncbi1N2ltpewROl0F3u8Ecvq5ojLZ5VA8jaOLlFbFojIgQCvZVfTdf-hdWuVYz6tU9a9lKzaOcEv5nErJFB7NINhNTnabk6052U1OFuvO26dXPG78TaUCYguUOoo3lJ98_azqHwJAm14</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1689584320</pqid></control><display><type>article</type><title>Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use</title><source>Publicly Available Content Database</source><source>Springer Nature - SpringerLink Journals - Fully Open Access </source><source>PubMed</source><creator>Ustianowski, Andrew ; Arends, Joop E.</creator><creatorcontrib>Ustianowski, Andrew ; Arends, Joop E.</creatorcontrib><description>Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.</description><identifier>ISSN: 2193-8229</identifier><identifier>EISSN: 2193-6382</identifier><identifier>DOI: 10.1007/s40121-015-0070-1</identifier><identifier>PMID: 26032649</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Antiretroviral drugs ; HIV ; Human immunodeficiency virus ; Infectious Diseases ; Internal Medicine ; Medicine ; Medicine &amp; Public Health ; Pharmacology ; Review ; Side effects ; Toxicity</subject><ispartof>Infectious diseases and therapy, 2015-06, Vol.4 (2), p.145-157</ispartof><rights>The Author(s) 2015</rights><rights>The Author(s) 2015. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-14b9faed91895579c28f963789f622140249f08fecc54d8816bc244c6d9e00e03</citedby><cites>FETCH-LOGICAL-c470t-14b9faed91895579c28f963789f622140249f08fecc54d8816bc244c6d9e00e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1689584320/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1689584320?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25751,27922,27923,37010,37011,44588,53789,53791,74896</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26032649$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ustianowski, Andrew</creatorcontrib><creatorcontrib>Arends, Joop E.</creatorcontrib><title>Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use</title><title>Infectious diseases and therapy</title><addtitle>Infect Dis Ther</addtitle><addtitle>Infect Dis Ther</addtitle><description>Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.</description><subject>Antiretroviral drugs</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Pharmacology</subject><subject>Review</subject><subject>Side effects</subject><subject>Toxicity</subject><issn>2193-8229</issn><issn>2193-6382</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp1kdFqVDEQhoNYbKl9AG8k4I03p87k5OQkXgiltFZY0YuW4lXIZiftKWeTmpxd8G18lj6ZWXYtVejVZJhv_vzDz9gbhGME6D8UCSiwAeya2kKDL9iBQNM2qtXi5e6thTD77KiUO4CKa4mmf8X2hYJWKGkO2NklxRTSesgf-fWtm_g18Qu3Jj4jl-PET8JEmffH3cPvr8M4Diny75RLis2PChSeAr8q9JrtBTcWOtrVQ3Z1fnZ5etHMvn3-cnoya7zsYWpQzk1wtDCoTdf1xgsdjGp7bYISAiUIaQLoQN53cqE1qrkXUnq1MARA0B6yT1vd-9V8SQtPccputPd5WLr8yyY32H8ncbi1N2ltpewROl0F3u8Ecvq5ojLZ5VA8jaOLlFbFojIgQCvZVfTdf-hdWuVYz6tU9a9lKzaOcEv5nErJFB7NINhNTnabk6052U1OFuvO26dXPG78TaUCYguUOoo3lJ98_azqHwJAm14</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Ustianowski, Andrew</creator><creator>Arends, Joop E.</creator><general>Springer Healthcare</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150601</creationdate><title>Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use</title><author>Ustianowski, Andrew ; Arends, Joop E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-14b9faed91895579c28f963789f622140249f08fecc54d8816bc244c6d9e00e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antiretroviral drugs</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Pharmacology</topic><topic>Review</topic><topic>Side effects</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ustianowski, Andrew</creatorcontrib><creatorcontrib>Arends, Joop E.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Infectious diseases and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ustianowski, Andrew</au><au>Arends, Joop E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use</atitle><jtitle>Infectious diseases and therapy</jtitle><stitle>Infect Dis Ther</stitle><addtitle>Infect Dis Ther</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>4</volume><issue>2</issue><spage>145</spage><epage>157</epage><pages>145-157</pages><issn>2193-8229</issn><eissn>2193-6382</eissn><abstract>Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>26032649</pmid><doi>10.1007/s40121-015-0070-1</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2193-8229
ispartof Infectious diseases and therapy, 2015-06, Vol.4 (2), p.145-157
issn 2193-8229
2193-6382
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4471058
source Publicly Available Content Database; Springer Nature - SpringerLink Journals - Fully Open Access ; PubMed
subjects Antiretroviral drugs
HIV
Human immunodeficiency virus
Infectious Diseases
Internal Medicine
Medicine
Medicine & Public Health
Pharmacology
Review
Side effects
Toxicity
title Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A27%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tenofovir:%20What%20We%20Have%20Learnt%20After%207.5%C2%A0Million%20Person-Years%20of%20Use&rft.jtitle=Infectious%20diseases%20and%20therapy&rft.au=Ustianowski,%20Andrew&rft.date=2015-06-01&rft.volume=4&rft.issue=2&rft.spage=145&rft.epage=157&rft.pages=145-157&rft.issn=2193-8229&rft.eissn=2193-6382&rft_id=info:doi/10.1007/s40121-015-0070-1&rft_dat=%3Cproquest_pubme%3E1690208645%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c470t-14b9faed91895579c28f963789f622140249f08fecc54d8816bc244c6d9e00e03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1689584320&rft_id=info:pmid/26032649&rfr_iscdi=true